Xenon Pharmaceuticals Inc (XENE) - Total Liabilities
Based on the latest financial reports, Xenon Pharmaceuticals Inc (XENE) has total liabilities worth $399.91 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of Xenon Pharmaceuticals Inc to see how much of total assets are deployed in long-term investments.
Xenon Pharmaceuticals Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Xenon Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see XENE asset base.
Xenon Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Xenon Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ningbo Jintian Copper Group Co Ltd
SHG:601609
|
China | CN¥18.37 Billion |
|
EQB Inc.
TO:EQB
|
Canada | CA$48.97 Billion |
|
Avicopter PLC
SHG:600038
|
China | CN¥35.62 Billion |
|
CleanSpark Inc
NASDAQ:CLSK
|
USA | $1.94 Billion |
|
Daeduck Electronics Co Ltd
KO:353200
|
Korea | ₩390.91 Billion |
|
Air France-KLM SA
PA:AF
|
France | €38.82 Billion |
|
National Energy Services Reunited Corp Ordinary Shares
NASDAQ:NESR
|
USA | $1.06 Billion |
|
INVENTURUS KNOWLEDGE SO L
NSE:IKS
|
India | Rs14.68 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Xenon Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See XENE net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.69 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Xenon Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Xenon Pharmaceuticals Inc (2012–2025)
The table below shows the annual total liabilities of Xenon Pharmaceuticals Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $399.91 Million | +824.95% |
| 2024-12-31 | $43.24 Million | +17.24% |
| 2023-12-31 | $36.88 Million | +12.95% |
| 2022-12-31 | $32.65 Million | +48.58% |
| 2021-12-31 | $21.97 Million | +23.23% |
| 2020-12-31 | $17.83 Million | -68.00% |
| 2019-12-31 | $55.72 Million | +191.22% |
| 2018-12-31 | $19.13 Million | +87.82% |
| 2017-12-31 | $10.19 Million | +184.08% |
| 2016-12-31 | $3.59 Million | +23.02% |
| 2015-12-31 | $2.92 Million | -80.09% |
| 2014-12-31 | $14.64 Million | -51.80% |
| 2013-12-31 | $30.37 Million | -40.08% |
| 2012-12-31 | $50.68 Million | -- |
About Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizure… Read more